<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Asia-Pacific</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730749</guid>
      <pubDate>Thu, 30 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730749-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>MFDS clears Curocell’s anbal-cel as first homegrown CAR T therapy </title>
      <description>
        <![CDATA[South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell Inc.’s <span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">Rimqarto&nbsp;</span>(anbalcabtagene-autoleucel; anbal-cel) April 29 as the first homegrown CAR T-cell therapy to treat patients with advanced diffuse large B-cell lymphomas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730685</guid>
      <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730685-mfds-clears-curocells-anbal-cel-as-first-homegrown-car-t-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Green-approved-stamp1.webp?t=1615578924" type="image/png" medium="image" fileSize="174851">
        <media:title type="plain">Green approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730686</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730686-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s new IIT rules could reshape early stage drug development </title>
      <description>
        <![CDATA[China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more multinational companies to conduct IITs in China, panelists said during the Chinabio Partnering Forum in Shanghai April 28-29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730684</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730684-chinas-new-iit-rules-could-reshape-early-stage-drug-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>Criminal charges filed against top Fauci aide </title>
      <description>
        <![CDATA[An alleged coverup of NIH-funded gain-of-function research at China’s Wuhan Institute of Virology has led to criminal charges against a former career scientist and top aide to Tony Fauci, the head of the National Institute of Allergy and Infectious Diseases in the time of the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730789</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730789-criminal-charges-filed-against-top-fauci-aide</link>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730787</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Akeso sets durability bar as immuno-oncology 2.0 race heats up </title>
      <description>
        <![CDATA[Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730786</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730786-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-metabolic-pancreas-anatomy-illustration.webp?t=1774020868" type="image/jpeg" medium="image" fileSize="655771">
        <media:title type="plain">Pancreas anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730785</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Cochlear’s 39% stock plunge resets ‘defensive growth’ narrative </title>
      <description>
        <![CDATA[Shares in Aussie hearing implant maker Cochlear Ltd. plummeted nearly 39% April 22 after the company slashed fiscal 2026 earnings guidance and warned that weaker-than-expected demand in developed markets was exposing a more cyclical and discretionary side to its business than investors had assumed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730783</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730783-cochlears-39-stock-plunge-resets-defensive-growth-narrative</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Cochlear-Nucleus-system-4-23.webp?t=1776975450" type="image/jpeg" medium="image" fileSize="214628">
        <media:title type="plain">Cochlear Nucleus system</media:title>
        <media:description type="plain">Nucleus Nexa cochlear implant system. Credit: Cochlear Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Pilatus PLT-012 takes immunometabolic approach to reprogram TME </title>
      <description>
        <![CDATA[Pilatus Bio Inc. is working to address a major under-addressed target of current checkpoint inhibitors: metabolic stress within solid tumors. “Traditional immunotherapies release immune ‘brakes,’ but they do not address the underlying metabolic stress in tumors,” Pilatus CEO and cofounder Raven Lin said. “That’s why more than 60% of solid tumor patients do not respond to treatment.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/730671</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730671-pilatus-plt-012-takes-immunometabolic-approach-to-reprogram-tme</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Monoclonal-antibody-cancer-tumor-illustration.webp?t=1765295036" type="image/jpeg" medium="image" fileSize="555950">
        <media:title type="plain">Illustration of monoclonal antibody treatment for cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinese biotechs gain leverage as partners in dealmaking</title>
      <description>
        <![CDATA[China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said during the Chinabio Partnering Forum in Shanghai April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730670</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730670-chinese-biotechs-gain-leverage-as-partners-in-dealmaking</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Chinabio-2026-partnering-4-28.webp?t=1777394174" type="image/jpeg" medium="image" fileSize="198615">
        <media:title type="plain">Chinabio 2026 partnering </media:title>
        <media:description type="plain">China’s evolution in the dealmaking arena was the hot topic of discussion on the first day of the Chinabio Partnering Forum.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730643</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730619</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730619-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest </title>
      <description>
        <![CDATA[A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything from epilepsy and narcolepsy to post-traumatic stress disorder and hyperphagia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730616</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730616-neuro-deals-aplenty-ucbs-1b-takeover-of-neurona-the-latest</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Epileptic-brain.webp?t=1648507237" type="image/png" medium="image" fileSize="319894">
        <media:title type="plain">Epileptic brain and abnormal EEG wave discharges</media:title>
      </media:content>
    </item>
    <item>
      <title>Cochlear’s 39% stock plunge resets ‘defensive growth’ narrative </title>
      <description>
        <![CDATA[Shares in Aussie hearing implant maker Cochlear Ltd. plummeted nearly 39% April 22 after the company slashed fiscal 2026 earnings guidance and warned that weaker-than-expected demand in developed markets was exposing a more cyclical and discretionary side to its business than investors had assumed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730605</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730605-cochlears-39-stock-plunge-resets-defensive-growth-narrative</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Cochlear-Nucleus-system-4-23.webp?t=1776975450" type="image/jpeg" medium="image" fileSize="214628">
        <media:title type="plain">Cochlear Nucleus system</media:title>
        <media:description type="plain">Nucleus Nexa cochlear implant system. Credit: Cochlear Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Akeso sets durability bar as immuno-oncology 2.0 race heats up </title>
      <description>
        <![CDATA[Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730500</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730500-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-metabolic-pancreas-anatomy-illustration.webp?t=1774020868" type="image/jpeg" medium="image" fileSize="655771">
        <media:title type="plain">Pancreas anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Delta-Fly eyes NDA path despite AML phase III miss </title>
      <description>
        <![CDATA[Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, instead leaning on earlier-stage efficacy signals and emerging combination data to support a potential path toward conditional approval.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730581</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730581-delta-fly-eyes-nda-path-despite-aml-phase-iii-miss</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Acute-myeloid-leukemia.webp?t=1588879994" type="image/png" medium="image" fileSize="485631">
        <media:title type="plain">Acute myeloid leukemia illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC</title>
      <description>
        <![CDATA[The U.S. FDA has accepted and granted priority review to Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.’s BLA of ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate (ADC) to treat patients with advanced extensive-stage small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730580</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730580-fda-grants-priority-review-to-merck-daiichis-b7-h3-cancer-adc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/lung-cancer.webp?t=1588881354" type="image/png" medium="image" fileSize="422296">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730579</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730579-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730578</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730578-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Pricing standoff leaves Australian patients in limbo</title>
      <description>
        <![CDATA[A pricing standoff between Pfizer Inc. and the Australian government has left women with advanced breast cancer facing tens of thousands of dollars in out-of-pocket costs, underscoring a growing global trend in which access to life-extending drugs is increasingly being shaped by pricing negotiations rather than clinical merit.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730577</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730577-pricing-standoff-leaves-australian-patients-in-limbo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/White-tabletl-with-dollar-sign-imprint.webp?t=1764186016" type="image/jpeg" medium="image" fileSize="192346">
        <media:title type="plain">White tablet imprinted with dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730574</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings steady at $8.8B in Q1, despite volume drop</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730573</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730573-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Layered-charts.webp?t=1706913970" type="image/jpeg" medium="image" fileSize="137002">
        <media:title type="plain">Layered  charts </media:title>
      </media:content>
    </item>
    <item>
      <title>Early data position Junshi in next-gen immuno-oncology race </title>
      <description>
        <![CDATA[Shanghai Junshi Biosciences Co. Ltd reported early clinical signals across its next-generation immuno-oncology pipeline, including response rates of up to 71% in metastatic colorectal cancer and 45.5% in hepatocellular carcinoma, at the American Association for Cancer Research meeting in San Diego.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730486</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730486-early-data-position-junshi-in-next-gen-immuno-oncology-race</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-and-immunotherapy.webp?t=1623784162" type="image/png" medium="image" fileSize="495987">
        <media:title type="plain">Illustration of cancer cells and immunotherapy treatment</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Kaleidoscope-like ‘engineered disorder’ expands imaging potential</title>
      <description>
        <![CDATA[A new metasurface design strategy that replaces rigid order with “engineered disorder” could significantly increase how many optical functions can be integrated into a single ultra-thin device without increasing size or complexity, according to a study published in <em>Nature Communications</em>. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730575</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730575-kaleidoscope-like-engineered-disorder-expands-imaging-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/kaleidoscope-pattern-art.webp?t=1776355120" type="image/jpeg" medium="image" fileSize="1285474">
        <media:title type="plain">Photo of kaleidoscope pattern</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic leads $100M financing round for Pulnovo</title>
      <description>
        <![CDATA[Pulnovo Medical Ltd. secured $100 million in a financing round led by Medtronic plc for its pulmonary artery denervation system to treat pulmonary hypertension. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730471</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730471-medtronic-leads-100m-financing-round-for-pulnovo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-financing.webp?t=1588371985" type="image/png" medium="image" fileSize="253228">
        <media:title type="plain">Hand holding gear, dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730470</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730470-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730409</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730409-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730407</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730407-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
  </channel>
</rss>
